10-Q: RCM Technologies Reports Q3 Revenue Growth Amid Profit Dip

RCM Technologies announced increased revenue for both the thirteen and thirty-nine weeks ended September 27, 2025, but reported a decline in net income and gross profit margins.

Summary

• Revenue for the thirteen weeks ended September 27, 2025, increased by $9.9 million (16.4%) to $70.3 million compared to $60.4 million in the prior-year period.
• Net income for the thirteen weeks decreased by $0.5 million (17.7%) to $2.3 million, down from $2.7 million in the prior-year period.
• Diluted net earnings per share for the thirteen weeks decreased to $0.30 from $0.35 in the prior-year period.
• Revenue for the thirty-nine weeks ended September 27, 2025, increased by $31.5 million (15.6%) to $232.9 million compared to $201.5 million in the prior-year period.
• Net income for the thirty-nine weeks decreased by $0.2 million (2.2%) to $10.2 million, down from $10.5 million in the prior-year period.
• Diluted net earnings per share for the thirty-nine weeks increased to $1.34 from $1.31 in the prior-year period.
• Gross profit margin for the thirteen weeks decreased to 27.6% from 29.6%, and for the thirty-nine weeks, it decreased to 27.3% from 28.9%.
• Specialty Health Care segment revenue increased by 13.0% for the thirteen weeks and 14.2% for the thirty-nine weeks, primarily driven by school clients.
• Engineering segment revenue increased by 30.0% for the thirteen weeks and 28.4% for the thirty-nine weeks, driven by Energy Services (EPC projects) and Aerospace expansion.
• Life Sciences, Data and Solutions segment revenue decreased by 8.0% for the thirteen weeks and 9.7% for the thirty-nine weeks, attributed to project timing and deemphasis on legacy staffing.
• Corporate selling, general and administrative (SGA) expenses increased by $0.8 million for the thirteen weeks and $2.5 million for the thirty-nine weeks, due to higher medical costs, executive equity compensation, and software technology investments.
• Cash provided by operating activities for the thirty-nine weeks was $7.5 million, a decrease from $7.8 million in the comparable prior-year period.
• The company had $37.1 million available for future treasury stock purchases as of September 27, 2025.

Sentiment

Score: 6

Explanation: The company demonstrates strong revenue growth in key segments and a clear strategic focus on high-demand technology solutions like AI and automation. However, this growth is offset by declining net income and gross profit margins, coupled with increased corporate expenses, indicating profitability pressures. Liquidity appears adequate, and the company is actively managing its capital structure through share repurchases and a potential ATM program. The mixed financial performance, despite strategic positives, warrants a neutral-to-slightly-positive sentiment.

Positives

• Strong revenue growth across the company, with a 16.4% increase for the thirteen weeks and 15.6% for the thirty-nine weeks ended September 27, 2025.
• Significant revenue increases in the Engineering segment (30.0% for thirteen weeks, 28.4% for thirty-nine weeks) driven by EPC projects and Aerospace expansion.
• Specialty Health Care segment also showed robust revenue growth (13.0% for thirteen weeks, 14.2% for thirty-nine weeks) due to existing and new school clients.
• Life Sciences, Data and Solutions segment improved its gross profit margin to 39.6% (thirteen weeks) and 39.7% (thirty-nine weeks) by emphasizing high-margin project work and achieving SGA efficiency.
• Operating income for the thirty-nine weeks increased by 6.7% to $17.1 million.
• The company remains in compliance with all financial covenants under its $65.0 million revolving credit facility and believes it can satisfy liquidity needs for at least the next twelve months.
• The company has $37.1 million available for future share repurchases under its Treasury Stock Repurchase Plan.

Negatives

• Net income decreased by 17.7% for the thirteen weeks ended September 27, 2025, to $2.3 million.
• Net income for the thirty-nine weeks ended September 27, 2025, slightly decreased by 2.2% to $10.2 million.
• Gross profit margins declined across the company, from 29.6% to 27.6% for the thirteen weeks and from 28.9% to 27.3% for the thirty-nine weeks.
• Operating income for the thirteen weeks decreased by 10.2% to $3.9 million.
• Corporate selling, general and administrative (SGA) expenses increased significantly, impacting overall profitability, due to higher medical costs, executive equity compensation, and software technology investments.
• Cash and cash equivalents decreased from $4.7 million at December 28, 2024, to $1.3 million at September 27, 2025.
• Cash used in operating activities for the thirty-nine weeks was $0.3 million less than the prior year, primarily due to a $9.3 million cash usage from net transit accounts receivable and payable fluctuations.

Risks

• A significant portion of consolidated revenues is contributed by a concentrated group of customers, particularly in the Specialty Health Care segment, posing customer concentration risk.
• Exposure to credit and collection risks on accounts receivable.
• Uncertainty regarding claim experience related to workers' compensation and general liability insurance.
• Potential adverse effects from changes in, or interpretations of, laws and regulations governing the healthcare industry, workforce, and services, including minimum wage increases and taxability of services.
• Sensitivity to unemployment and general economic conditions, which can substantially impact revenue and operations.
• Challenges in attracting, training, and retaining personnel qualified to meet client requirements.
• Difficulties in identifying appropriate acquisition candidates, completing such acquisitions, and successfully integrating acquired businesses.
• Reliance on significant customers and the ability to collect accounts receivable from them.
• Risks associated with foreign currency fluctuations and changes in exchange rates, particularly with respect to the Canadian dollar.
• Uncertainties regarding amounts of deferred consideration and earnout payments for acquired businesses.
• Potential adverse effect of a decrease in the common stock trading price on the ability to acquire businesses through the issuance of securities.
• Ability to obtain financing on satisfactory terms.
• Reliance upon the continued service of executive officers.
• Ability to remain competitive in highly competitive global, national, regional, and local markets with significant price competition.
• Ability to maintain unemployment insurance premiums and workers' compensation premiums.
• Risk of claims being made against the company associated with providing temporary staffing services.
• Ability to manage significant amounts of information and periodically expand and upgrade information processing capabilities, including cyber attack risks.
• Ability to remain in compliance with federal and state wage and hour laws and regulations.
• Uncertainties in predictions as to the future need for the company's services.
• Uncertainties relating to the allocation of costs and expenses to each operating segment.
• Costs and outcomes of litigation, arbitrations, and other business disputes, and the applicability of insurance coverage.
• Potential interactions with shareholders who may pursue specific initiatives with respect to governance and strategic direction, including contested proxy solicitations.
• Other geopolitical, economic, competitive, health, and governmental factors affecting operations, markets, products, and services.

Future Outlook

The company anticipates continued demand for outsourcing in advanced technologies like Artificial Intelligence (AI), Quality by Design (QbD), and process automation, believing businesses must implement these solutions to upgrade systems. It aims to expand sales of higher-margin solutions and project management services. The company expects to maintain compliance with financial covenants and believes it can satisfy liquidity needs for at least the next twelve months. Future capital uses will primarily be for working capital, with funding for long-term requirements and acquisitions potentially from the revolving credit facility, operations, or future financing transactions.

Management Comments

• The company believes it has developed and assembled an attractive portfolio of capabilities, established a proven record of performance and credibility, and built an efficient pricing structure.
• The company is committed to optimizing its business model as a single-source premier provider of business and technology solutions with a strong vertical focus offering an integrated suite of services through a global delivery platform.
• The company believes that businesses must implement more advanced life sciences, information technology, and engineering solutions—including Artificial Intelligence (AI) specifically Agentic AI, Quality by Design (QbD), and process automation—to upgrade their systems, applications, and processes.
• The demand for outsourcing—especially in areas involving AI, QbD, and automation—continues to rise as companies are driven to support increasingly complex systems, applications, and processes of significant strategic value.
• The company generally endeavors to expand its sales of higher margin solutions and project management services.
• The company believes it has a great deal of flexibility to reduce its costs if it becomes necessary.
• The company believes that it can satisfy its liquidity needs for at least the next twelve months.

Industry Context

RCM Technologies operates in a cyclical market sensitive to economic changes, where businesses are increasingly focused on return on investment for new solutions. Despite this, the company highlights a growing demand for outsourcing in advanced technologies such as Artificial Intelligence (AI), Quality by Design (QbD), and process automation, which are crucial for upgrading systems and enhancing operational efficiency. The consulting and employment services market is highly competitive with numerous players and significant pricing pressures, which the company expects to remain high.

Corporate Governance

Legal Proceedings

• The company is a defendant in various legal actions arising in the ordinary course of business, including matters related to professional liability, tax, compensation, contract, competitor disputes, and employee-related issues.
• As of September 27, 2025, the company had accrued $0.4 million for asserted claims where a probability of loss is believed to exist.
• The company is also exposed to other asserted claims where the amount of loss has not been declared and cannot be determined.
• Management believes that these matters, individually or in aggregate, will not have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Experience mixed financial results with revenue growth but declining net income and gross margins. The share repurchase program and potential ATM program could impact share value and dilution.
• Employees: Benefit from equity compensation plans, but also face increased medical costs reflected in corporate SGA.
• Customers: Continue to receive advanced technology solutions, with a strategic emphasis on AI, QbD, and automation, potentially leading to enhanced service offerings.
• Creditors: The company remains in compliance with all financial covenants under its revolving credit facility, indicating a stable credit position.
• Suppliers/Subcontractors: The company's transit accounts payable and receivable fluctuations, particularly related to EPC projects, impact cash flow dynamics with subcontractors.

Next Steps

• Continue to recognize compensation expense for time-based non-vested share-based awards through fiscal 2035.
• Recognize compensation expense for performance-based non-vested share-based awards through fiscal 2030, if performance metrics are achieved.
• Evaluate the impact of new accounting standards (ASU 2023-09, 2024-03, 2025-05, 2025-06) on future disclosures and financial statements.
• Potentially pursue strategic acquisitions, which may require incurring debt or issuing dilutive securities.
• Potentially utilize the At Market Issuance Sales Agreement (ATM Program) to raise capital by selling common stock.

Key Dates

Recommendation

RCM Technologies exhibits strong revenue growth, particularly in its Engineering and Specialty Health Care segments, driven by strategic initiatives in high-demand areas like EPC projects and school contracts. The company's focus on high-margin project work in Life Sciences, Data and Solutions is also positive. However, these positives are tempered by a decline in net income and gross profit margins across the board, alongside increased corporate overhead expenses. While liquidity appears sufficient and the company is actively managing its capital structure through share repurchases, the profitability pressures warrant a cautious stance. The mixed performance suggests that while there is growth potential, the company faces challenges in translating top-line growth into improved bottom-line results. Therefore, a 'hold' recommendation is appropriate for investors to observe if the company can improve its profitability and gross margins in future periods.

Keywords

IT consulting, Engineering services, Healthcare staffing, Life sciences solutions, Data solutions, AI, Agentic AI, Quality by Design, QbD, Process automation, Staff augmentation, SEC filing, 10-Q, Quarterly report, Financial results